Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.

被引：0
|
作者：
Moon, Helen H. [1 ]
Kearney, Mairead [2 ]
Mahmoudpour, Seyed Hamidreza [2 ]
Ike, Chiemeka [3 ]
Morris, Valerie A. [3 ]
Rava, Andrew [4 ]
Kim, Sonia [5 ]
Sun, Haiyan [5 ]
Boyd, Marley [5 ]
Rey, Gabriel Gomez [5 ]
机构：
[1] Kaiser Permanente, Riverside, CA USA
[2] Healthcare Business Merck KGaA, Darmstadt, Germany
[3] EMD Serono, Rockland, MA USA
[4] Genesis Res, Hoboken, NJ USA
[5] Genesis Res LLC, Hoboken, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-12268; 130-544; 261-492-9019; 298-145-222-9001; 261-492-3532-2370-7650-2700; 261-566-9263; 6; 4; 3; 2; 1880; 1876; 3224; 295; 12; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：605 / 605
页数：1
相关论文
共 50 条
  • [1] Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
    Carson, K.
    Mahmoudpour, H.
    Ike, C.
    Monzon, S.
    Fragkogianni, S.
    Ferrer, J.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1215 - S1216
  • [2] Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM)
    Carson, Kenneth Robert
    Ike, Chiemeka
    Mahmoudpour, Seyed Hamidreza
    Monzon, Sebastian
    Fragkogianni, Stamatina
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States
    Moon, Helen H.
    Kearney, Mairead
    Mahmoudpour, Seyed Hamidreza
    Ike, Chiemeka
    Morris, Valerie
    Rava, Andrew
    Kim, Sonia
    Sun, Haiyan
    Boyd, Marley
    Gomez Rey, Gabriel
    CURRENT ONCOLOGY, 2024, 31 (09) : 5662 - 5676
  • [4] READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/ mUC).
    Antonuzzo, Lorenzo
    Maruzzo, Marco
    De Giorgi, Ugo
    Santini, Daniele
    Tambaro, Rosa
    Buti, Sebastiano
    Carrozza, Francesco
    Calabro, Fabio
    Di Lorenzo, Giuseppe
    Fornarini, Giuseppe
    Iacovelli, Roberto
    Cullura, Daniela
    Messina, Carlo
    Masi, Claudia
    Ciccia, Angelo
    Fazzi, Gennaro
    Venturini, Filippo
    Colasanto, Raffaele
    Necchi, Andrea
    Bracarda, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
    Zemankova, Anezka
    Studentova, Hana
    Melichar, Bohuslav
    Eid, Michal
    Poprach, Alexandr
    Kopecky, Jindrich
    Spacek, Jan
    Stuhlova, Sarka
    Dvorak, Jan
    Vlcek, Pavel
    Zychackova, Katerina
    Katolicka, Jana
    Blazek, Tomas
    Vrana, David
    Majkova, Petra
    Cepa, Adam
    Fiala, Ondrej
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 557 - 557
  • [6] Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US.
    Kearney, Mairead
    Mahmoudpour, Hamid
    Ike, Chiemeka
    Modh, Ambar
    Monzon, Sebastian
    Fragkogianni, Matina
    Carson, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
    Park, S. H.
    Jo, J.
    Kim, M.
    Shin, S. J.
    Kim, I-H.
    Huang, Y-H.
    Tsai, Y-C.
    Oliveira, N.
    Rajappa, S. J.
    Wang, Y.
    Hoffman, J.
    Su, P. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1508 - S1509
  • [8] Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II).
    Grivas, Petros
    Barata, Pedro C.
    Moon, Helen
    Hutson, Thomas E.
    Gupta, Shilpa
    Sternberg, Cora N.
    Dave, Vaidehi
    Downey, Chad
    Shillington, Alicia C.
    Devgan, Geeta
    Kirker, Melissa
    Thakkar, Sheena
    Katzenstein, Howard M.
    Bhanegaonkar, Abhijeet
    Liu, Frank
    Brown, Jason
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
    Barthelemy, P.
    Loriot, Y.
    Flechon, A.
    Goupil, M. Gross
    Voog, E.
    Eymard, J-C.
    Lorgis, V.
    Pouessel, D.
    Francois, L.
    Sajous, C.
    Bouju, D. Chocteau
    Guillot, A.
    Long, J.
    Amela, E.
    Josse, C.
    Solbes, M-N.
    Lambert, P.
    Thibault, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1211 - S1212
  • [10] Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)
    Bracarda, Sergio
    Antonuzzo, Lorenzo
    Maruzzo, Marco
    Santini, Daniele
    Tambaro, Rosa
    Buti, Sebastiano
    Carrozza, Francesco
    Calabro, Fabio
    Di Lorenzo, Giuseppe
    Fornarini, Giuseppe
    Iacovelli, Roberto
    Cullura, Daniela
    Messina, Carlo
    Cerbone, Linda
    Fazzi, Gennaro
    Venturini, Filippo
    Colasanto, Raffaele
    Necchi, Andrea
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 558 - 558
12345